U.S. imports of medicaments in measured doses or retail packaging, nesoi (HS 300490) totaled $5.7B in August 2026, imported from 66 countries.
Importers of Medicaments in Measured Doses or Retail Packaging, NESOI paid $2.3M in duties in August 2026, an effective tariff rate of 0.04% of the $5.7B imported — duty actually collected as a share of that value, not the published tariff schedule.
Last updated: August 2026 dataFDA regulates all finished pharmaceutical imports under this heading, requiring that each shipment originate from a registered foreign establishment and be accompanied by documentation sufficient to support admissibility review; FDA may detain or refuse entry without prior notice. The heading is a catch-all for formulated medicaments not captured by more specific headings covering antibiotics, hormones, or alkaloids, and the US 10-digit schedule is unusually granular — distinguishing antivirals by active ingredient (acyclovir, oseltamivir, valganciclovir), antifungals, cardiovascular agents by molecule, and veterinary preparations. Ireland and Switzerland are the leading suppliers, reflecting the concentration of multinational pharmaceutical manufacturing in those jurisdictions, with India a major source of generic finished-dose products. Importers should work with a licensed customs broker experienced in pharmaceutical entry to navigate FDA's Prior Notice and drug registration requirements.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
15.3K shipments/mo
All finished pharmaceutical imports require FDA Prior Notice submission before arrival, and the foreign manufacturer must be registered with FDA under the Drug Establishment Registration program. FDA may conduct physical examination or sampling at the port of entry, and shipments from unregistered facilities or those on import alert are subject to automatic detention. Importers should verify the foreign establishment's registration status and any active import alerts before shipment.
The US schedule breaks out antivirals by specific active ingredient — separate lines exist for acyclovir, oseltamivir, and valganciclovir/peramivir, among others — and cardiovascular agents are similarly split by molecule (metoprolol, amiodarone, diltiazem, enoxaparin, and others). Correct 10-digit classification is essential because duty rates, statistical reporting, and potential trade-remedy applicability can differ across lines. Misclassifying a named active ingredient into a residual 'NESOI' line is a common error that can trigger CBP penalties.
HSChapter 30
ImportsExports
Imports
$5.7BYoY · free account
Exports
$1.8BYoY · free account
12-mo low · imports
YoY · free accountOver the twelve months to August 2026, the U.S. imported $62.7B of Medicaments in Measured Doses or Retail Packaging, NESOI.
Through August 2026. Source: U.S. Census Bureau.
Trade Directory
List your company under HS 300490 — Medicaments in Measured Doses or Retail Packaging, NESOI, so the companies trading it can find you. Be the first supplier listed.
Subheading 1 of 12 in heading 3004
Subheading 300490 · $5.7B of $7.1B
Imports · August 2026
origin
customs district
destination
entry
rate provision · imports
98.6% enters free of duty; duty collected equals 0.04% of total import value.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.